Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VY1706 Low dose · 1 trial · 1 indication
Incidence of treatment emergent adverse events, clinically significant changes from baseline in vital signs, physical and neurological exams, Columbia Suicide-Severity Rating Scale, Electrocardiogram, Clinical lab parameters and transthoracic echocardiogram
| Arm | Type | Description |
|---|---|---|
| Low dose IV Infusion | EXPERIMENTAL | - |
| Mid dose IV Infusion | EXPERIMENTAL | - |
| High dose IV Infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VY1706 Low dose | DRUG | Low dose |
| VY1706 Mid dose | DRUG | Mid Dose |
| VY1706 High Dose | DRUG | High dose |
| Anti-AAV9 Total Antibody (TAb) Assay | DEVICE | Anti-AAV9 Total Antibody (TAb) Assay |
Inclusion Criteria: * Male or female participants aged 55 to 80 years (inclusive) at Screening or aged 30 to 80 years (inclusive) if presence of a historically documented dominantly inherited mutation associated with monogenic AD. * Clinical diagnosis of mild cognitive impairment (MCI) due to AD or...
Top 20 of 24 competitors
VY1706 Low dose is an investigational small molecule being studied for the treatment of early Alzheimer's Disease. It is currently in Phase 1 clinical development, with an open-label dose escalation study planned to evaluate its safety and tolerability in participants with early Alzheimer's Disease.
VY1706 Low dose is being developed by Voyager Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VYGR. The company is conducting a Phase 1 clinical trial to evaluate the drug in participants with early Alzheimer's Disease.
VY1706 Low dose is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in an open-label dose escalation trial for early Alzheimer's Disease. The trial is not yet recruiting participants.
VY1706 Low dose is being evaluated in a single Phase 1 clinical trial, identified as NCT07764146. This is an open-label, dose escalation study in participants with early Alzheimer's Disease, with an estimated enrollment of 18 participants. The trial is not yet recruiting.
VY1706 Low dose is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for early Alzheimer's Disease. The ongoing trial, NCT07764146, is an open-label dose escalation study that has not yet begun recruiting participants.